Idorsia Ltd (IDIA.SW) SIX

3.38

+0.31(+10.10%)

Updated at September 09 05:30PM

Currency In CHF

Idorsia Ltd

Address

Hegenheimermattweg 91

Allschwil, 4123

Switzerland

Phone

41 58 844 10 10

Sector

Healthcare

Industry

Biotechnology

Employees

636

First IPO Date

June 16, 2017

Key Executives

NameTitlePayYear Born
Mr. Andre C. MullerChief Executive Officer01963
Dr. Martine ClozelExecutive Vice President & Chief Scientific Officer01955
Andrew JonesSenior Vice President, Head of Corporate Communications & Investor Relations01975
Mr. Markus A. RiedererSenior Vice President & Head of Drug Discovery Biology01962
Mr. Christoph BossSenior Vice President & Head of Drug Discovery Chemistry01968
Arno GroenewoudExecutive Vice President & Chief Financial Officer01971
Mr. Olivier LambertSenior Vice President & Head of Technical Operations01966
Mr. Alberto Gimona M.D.Executive Vice President & Head of Global Clinical Development01960
Mr. Julien Gander L.L.M.Senior Vice President, Group General Counsel & Company Secretary01979
Mr. Alexander KhatuntsevSenior Vice President & Head of Global Human Resources01978

Description

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.